CEL-SCI (NYSE:CVM) Trading Down 2.5%

CEL-SCI Co. (NYSE:CVM)’s stock price dropped 2.5% during mid-day trading on Wednesday . The company traded as low as $1.16 and last traded at $1.19. Approximately 103,219 shares were traded during trading, a decline of 67% from the average daily volume of 311,925 shares. The stock had previously closed at $1.22.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded CEL-SCI from a “hold” rating to a “sell” rating in a research report on Friday, March 15th.

CEL-SCI Stock Performance

The stock has a fifty day simple moving average of $1.27 and a two-hundred day simple moving average of $1.86. The stock has a market cap of $68.51 million, a price-to-earnings ratio of -2.01 and a beta of 0.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.18 and a current ratio of 1.67.

CEL-SCI (NYSE:CVM) last issued its earnings results on Thursday, May 16th. The company reported ($0.14) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.14). Analysts expect that CEL-SCI Co. will post -0.51 EPS for the current fiscal year.

Insider Activity

In related news, Director Robert Eugene Watson bought 20,000 shares of the stock in a transaction that occurred on Wednesday, May 8th. The stock was acquired at an average cost of $1.39 per share, with a total value of $27,800.00. Following the transaction, the director now directly owns 24,431 shares in the company, valued at $33,959.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other CEL-SCI news, CEO Geert R. Kersten acquired 30,000 shares of the company’s stock in a transaction dated Wednesday, May 8th. The shares were bought at an average cost of $1.39 per share, with a total value of $41,700.00. Following the purchase, the chief executive officer now directly owns 1,195,309 shares of the company’s stock, valued at $1,661,479.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert Eugene Watson acquired 20,000 shares of the company’s stock in a transaction dated Wednesday, May 8th. The stock was acquired at an average cost of $1.39 per share, for a total transaction of $27,800.00. Following the completion of the purchase, the director now directly owns 24,431 shares in the company, valued at $33,959.09. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 58,000 shares of company stock worth $80,620. Insiders own 16.24% of the company’s stock.

Institutional Trading of CEL-SCI

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CVM. CVI Holdings LLC bought a new stake in CEL-SCI in the 1st quarter valued at about $1,678,000. D.A. Davidson & CO. increased its position in CEL-SCI by 564.2% in the 4th quarter. D.A. Davidson & CO. now owns 290,928 shares of the company’s stock valued at $791,000 after buying an additional 247,128 shares in the last quarter. Cantor Fitzgerald L. P. bought a new stake in CEL-SCI in the 4th quarter valued at about $329,000. Vanguard Group Inc. increased its position in CEL-SCI by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 2,193,327 shares of the company’s stock valued at $4,189,000 after buying an additional 113,703 shares in the last quarter. Finally, Vontobel Holding Ltd. bought a new stake in CEL-SCI in the 4th quarter valued at about $68,000. 12.08% of the stock is owned by institutional investors.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.